ClinicalTrials.Veeva

Menu

Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl

A

Assistance Publique - Hôpitaux de Paris

Status

Unknown

Conditions

Pain

Treatments

Drug: remifentanyl

Study type

Interventional

Funder types

Other

Identifiers

NCT00162591
P040201 AT/AT/04-116

Details and patient eligibility

About

The aim of this protocol is to study the prophylactic effect of remifentanil on bispectral index variation during a nociceptive stimuli.

Full description

Pain is difficult to estimate in ICU because most of the patients are sedated. Bispectral index could be helpful in detecting this pain in ICU patients. Remifentanil is a morphinomimetic product with short half life that could be interesting for short nociceptive stimuli, as bronchoalveolar lavage.

The purpose of this study is to evaluate the impact of remifentanil infusion on bispectral index (BIS) variations during bronchoalveolar lavage.

It is a prospective, double blind study, versus placebo on 40 sedated and critically ill patients.

The hypothesis is that BIS can study analgesia in sedated patient.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Sedated patient with mechanical ventilation with suspected nosocomial pneumonia

Exclusion criteria

  • Pace maker
  • Neurologic illness
  • Hemodynamic instability
  • Hypothermia

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Central trial contact

QUINTARD h Hervé, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems